Pfizer Amends In-House RNAi Rx Guidance

The big pharma's Research Technology Center still anticipates filing an IND before the end of 2011, but now expects it to be for "an in-house nucleic acid drug" in 2011 rather than one necessarily based on RNAi.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.